Naomi Kresge

Boehringer Ingelheim GmbH is pitching its experimental obesity drug as a way to help patients lose fat while preserving muscle, providing a potential edge in the crowded market for weight-loss medicines.

The race for no. 3 in obesity drugs just got tougher.

A disputa pelo terceiro lugar no mercado de medicamentos contra obesidade ficou mais difícil.

Chemist4U already has a waiting list of more than 10,000 customers interested in Novo Nordisk A/S’s Wegovy pill, which the online pharmacy said it expects will reach the UK market soon.

Novo Nordisk A/S’s Wegovy pill was approved in the UK, opening up the obesity market to people who are wary of taking a shot.

Novo Nordisk A/S said it had identified unauthorized access to some IT systems the drugmaker uses for its global business.

Germany signaled it will move ahead with plans to impose lower drug prices on pharmaceutical companies, calling a US accusation of unfair trade practices “unfounded.”

Novo Nordisk A/S said its market research shows twice as many US Medicare recipients would rather take a weight-loss pill over a shot, a preference the Danish drugmaker will try to use to grab market share from its rival Eli Lilly & Co.

The European Medicines Agency recommended that CSL Ltd.’s drug Tavneos be pulled from the market after finding it was approved based on allegedly incorrect and misleading data, adding pressure to its US manufacturer, Amgen Inc.

Abivax SA soared as much as 27% after a clinical-trial update soothed some investors’ concerns about whether cancer could be a potential side effect of the biotech’s most promising experimental drug.